IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner.

Abstract:

:Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent on the type of cancer and local microenvironment, AREG may induce tumour cell proliferation, invasion, migration or resistance to apoptosis by signaling through the epidermal growth factor receptor (EGFR). We have found that IL-33 is dramatically increased in and around metastatic tumour foci in the lungs of mice bearing orthotopic murine mammary tumours. We observed that Tregs express significantly more of the IL-33 receptor, ST2, relative to conventional T cells, that ST2+ Tregs accumulate in the lungs of metastatic tumour-bearing mice, and that ST2+ Tregs produce significantly more AREG than ST2- Tregs. The intranasal administration of recombinant IL-33 increased the proportion of AREG producing ST2+ Tregs and enhanced the level of phosphorylated EGFR in the metastatic lungs. While recombinant AREG did not impact mammary tumour cell proliferation in vitro despite inducing a dose-dependent increase in phosphorylated EGFR, intranasal administration of AREG resulted in a ten-fold increase in pulmonary metastatic tumour burden in vivo. Further, the intranasal administration of recombinant IL-33 significantly increased metastatic tumour burden in the lungs in an amphiregulin-dependent manner. These data identify ST2+ Tregs as a microenvironmental source of AREG in the lungs of mice with orthotopic metastatic mammary tumours and highlight an important role for AREG in promoting metastatic tumour growth in the lungs.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Halvorsen EC,Franks SE,Wadsworth BJ,Harbourne BT,Cederberg RA,Steer CA,Martinez-Gonzalez I,Calder J,Lockwood WW,Bennewith KL

doi

10.1080/2162402X.2018.1527497

subject

Has Abstract

pub_date

2018-10-16 00:00:00

pages

e1527497

issue

2

eissn

2162-4011

issn

2162-402X

pii

1527497

journal_volume

8

pub_type

杂志文章
  • Invariant NKT cells: Killers and conspirators against cancer.

    abstract::Although invariant natural killer T (iNKT) cells influence antitumor responses indirectly by secreting cytokines and promoting the cytolytic functions of T and NK cells, we find that iNKT cells mediate direct tumoricidal activity in vitro and significantly inhibit tumor growth in vivo, even in the absence of other cyt...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27440

    authors: Bassiri H,Das R,Nichols KE

    更新日期:2013-12-01 00:00:00

  • Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity.

    abstract::The inspection of the mechanisms through which autophagy modulates immunogenic cell death revealed that the autophagic response of cancer cells to reactive oxygen species-dependent endoplasmic reticulum stress suppresses the exposure of calreticulin on the cell surface, the phenotypic maturation of dendritic cells (DC...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26260

    authors: Garg AD,Dudek AM,Agostinis P

    更新日期:2013-10-01 00:00:00

  • Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

    abstract::We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.29312

    authors: Pearce OM,Läubli H,Bui J,Varki A

    更新日期:2014-06-25 00:00:00

  • Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

    abstract::Immunomodulation is an important part of lenalidomide's mode of action. We analyzed the impact of lenalidomide on T cells from patients with multiple myeloma during lenalidomide therapy in vivo and in patients with lenalidomide-refractory disease in vitro Patients enrolled in the German Speaking Myeloma Multicenter Gr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1139662

    authors: Krämer I,Engelhardt M,Fichtner S,Neuber B,Medenhoff S,Bertsch U,Hillengass J,Raab MS,Hose D,Ho AD,Goldschmidt H,Hundemer M

    更新日期:2016-02-18 00:00:00

  • Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer.

    abstract::Although high levels of tumor-infiltrating lymphocytes (TILs) generally correlate with good prognosis in high-grade serous ovarian cancer (HGSC) patients, little is known about the phenotype or specificity of these cells. We have recently demonstrated that TIL expressing the intra-epithelial lymphocyte marker CD103 (o...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27668

    authors: Webb JR,Milne K,Nelson BH

    更新日期:2014-01-10 00:00:00

  • Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.

    abstract::LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1338236

    authors: Nestvold J,Wang MY,Camilio KA,Zinöcker S,Tjelle TE,Lindberg A,Haug BE,Kvalheim G,Sveinbjørnsson B,Rekdal Ø

    更新日期:2017-06-16 00:00:00

  • Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

    abstract::Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II i...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1438106

    authors: Luo N,Formisano L,Gonzalez-Ericsson PI,Sanchez V,Dean PT,Opalenik SR,Sanders ME,Cook RS,Arteaga CL,Johnson DB,Balko JM

    更新日期:2018-03-06 00:00:00

  • A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.

    abstract::Immunotherapy with oncolytic herpes simplex virus-1 therapy offers an innovative, targeted, less-toxic approach for treating brain tumors. However, a major obstacle in maximizing oncolytic virotherapy is a lack of comprehensive understanding of the underlying mechanisms that unfold in CNS tumors/associated microenviro...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1678921

    authors: Bernstock JD,Vicario N,Rong L,Valdes PA,Choi BD,Chen JA,DiToro D,Osorio DS,Kachurak K,Gessler F,Johnston JM Jr,Atkinson TP,Whitley RJ,Bag AK,Gillespie GY,Markert JM,Maric D,Friedman GK

    更新日期:2019-10-21 00:00:00

  • Trial watch: Dendritic cell-based anticancer immunotherapy.

    abstract::Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2017.1328341

    authors: Garg AD,Vara Perez M,Schaaf M,Agostinis P,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2017-05-12 00:00:00

  • Protective function of interleukin 27 in colitis-associated cancer via suppression of inflammatory cytokines in intestinal epithelial cells.

    abstract::Numerous studies have demonstrated that inflammation contributes to a variety of cancer formation, among them, colitis-associated cancer (CAC) represents a typical inflammation-related cancer. Interleukin 27 (IL-27) has been demonstrated to play an important role in inflammation-related disease. The effect of IL-27 in...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1268309

    authors: Cui B,Lu S,Lai L,Xie Y,He J,Xue Y,Xiao P,Pan T,Chen L,Liu Y,Cao X,Wang Q

    更新日期:2017-01-20 00:00:00

  • A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

    abstract::Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1421890

    authors: Choi JH,Kim KH,Roh KH,Jung H,Lee A,Lee JY,Song JY,Park SJ,Kim I,Lee WS,Seo SK,Choi IW,Fu YX,Yea SS,Park S

    更新日期:2018-01-16 00:00:00

  • Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

    abstract::An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activa...

    journal_title:Oncoimmunology

    pub_type: 评审

    doi:10.4161/2162402X.2014.985940

    authors: Vacchelli E,Pol J,Bloy N,Eggermont A,Cremer I,Fridman WH,Galon J,Marabelle A,Kohrt H,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2015-02-03 00:00:00

  • Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.

    abstract::Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2014.1002726

    authors: Mella M,Kauppila JH,Karihtala P,Lehenkari P,Jukkola-Vuorinen A,Soini Y,Auvinen P,Vaarala MH,Ronkainen H,Kauppila S,Haapasaari KM,Vuopala KS,Selander KS

    更新日期:2015-05-22 00:00:00

  • Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

    abstract::The prostaglandin (PG) synthetase cyclooxygenase 2 (Cox-2) promotes tumorigenesis, tumor progression, and metastasis in a variety of human cancer entities including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrate that in PDAC cells such as Colo357 cells, enhanced Cox-2 expression and increased r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.988460

    authors: Gonnermann D,Oberg HH,Kellner C,Peipp M,Sebens S,Kabelitz D,Wesch D

    更新日期:2015-01-07 00:00:00

  • IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

    abstract::Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that fail to be controlled by protective immune mechanisms. In this study, we focused on IL-32, a cytokine, highly expressed in MF lesions. Depending on the other cytokines (IL-4, GM-CSF) present during in vitro culture of he...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1181237

    authors: Ohmatsu H,Humme D,Gonzalez J,Gulati N,Möbs M,Sterry W,Krueger JG

    更新日期:2016-05-05 00:00:00

  • The role of NF-kB in modulating antitumor immunity.

    abstract::Recent breakthroughs in therapeutic modulation of immune cells have led to novel exciting treatments for cancers. Moreover, the cytokine milieu in the tumor microenvironment is important for appropriate immune surveillance. Here, we demonstrate that NF-κB activity in myeloid cells is essential for cytokine-mediated an...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1005522

    authors: Richmond A,Yang J

    更新日期:2015-10-20 00:00:00

  • The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression.

    abstract::Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMX...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1346765

    authors: Weiss JM,Guérin MV,Regnier F,Renault G,Galy-Fauroux I,Vimeux L,Feuillet V,Peranzoni E,Thoreau M,Trautmann A,Bercovici N

    更新日期:2017-07-07 00:00:00

  • Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

    abstract::Oncolytic virotherapy is an emergent promising therapeutic approach for the treatment of cancer. We have constructed a vaccinia virus (WR strain) deleted for thymidine kinase (TK) and ribonucleotide reductase (RR) genes that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil ph...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1080414

    authors: Fend L,Remy-Ziller C,Foloppe J,Kempf J,Cochin S,Barraud L,Accart N,Erbs P,Fournel S,Préville X

    更新日期:2015-10-06 00:00:00

  • Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?

    abstract::Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1596006

    authors: Davola ME,Mossman KL

    更新日期:2019-03-28 00:00:00

  • Acute myeloid leukemia and NK cells: two warriors confront each other.

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2018.1539617

    authors: Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

    更新日期:2018-10-31 00:00:00

  • Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

    abstract::Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. A...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1518672

    authors: Tan Z,Liu L,Chiu MS,Cheung KW,Yan CW,Yu Z,Lee BK,Liu W,Man K,Chen Z

    更新日期:2018-10-16 00:00:00

  • Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer.

    abstract::The blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific T cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. This can boost the efficacy of adoptive T-cell therapy to achieve superior ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22691

    authors: Peng W,Lizée G,Hwu P

    更新日期:2013-02-01 00:00:00

  • The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone.

    abstract::Breast cancer spread to distant sites is often incurable. Our recent findings demonstrate that Type I interferons secreted by tumor cells induce anti-metastatic immune responses that prevent breast cancer metastasis to the bone. This provides novel insights into the importance of the crosstalk between neoplastic and i...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22339

    authors: Slaney CY,Möller A,Hertzog PJ,Parker BS

    更新日期:2013-01-01 00:00:00

  • In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

    abstract::The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.946360

    authors: Ruben JM,Bontkes HJ,Westers TM,Hooijberg E,Ossenkoppele GJ,van de Loosdrecht AA,de Gruijl TD

    更新日期:2014-07-03 00:00:00

  • Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.

    abstract::Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a novel treatment approach involving repeated subcutaneous delivery of a ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1398875

    authors: Bazett M,Costa AM,Bosiljcic M,Anderson RM,Alexander MP,Wong SWY,Dhanji S,Chen JM,Pankovich J,Lam S,Sutcliffe S,Gunn H,Kalyan S,Mullins DW

    更新日期:2017-11-27 00:00:00

  • CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

    abstract::CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1424677

    authors: Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

    更新日期:2018-02-01 00:00:00

  • The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy.

    abstract::Renal cell carcinoma (RCC) is an immunogenic tumor, but uses several immune-suppressive mechanisms to shift the balance from tumor immune response toward tumor growth. Although RCC has traditionally been considered to be radiation resistant, recent evidence suggests that hypofractionated radiotherapy contributes to sy...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2015.1042198

    authors: De Wolf K,Vermaelen K,De Meerleer G,Lambrecht BN,Ost P

    更新日期:2015-05-27 00:00:00

  • IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.

    abstract::The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1806662

    authors: Richardson LG,Nieman LT,Stemmer-Rachamimov AO,Zheng XS,Stafford K,Nagashima H,Miller JJ,Kiyokawa J,Ting DT,Wakimoto H,Cahill DP,Choi BD,Curry WT

    更新日期:2020-08-20 00:00:00

  • Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo: Enhanced gene transfer and adjuvant activity.

    abstract::DNA vaccination consists of administering an antigen-coding nucleotide sequence. In order to improve the efficacy of DNA vaccines, electroporation is one of the most commonly used methods to enhance DNA uptake. Here, we discuss additional immunological effects of electroporation that are key aspects for inducing immun...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28540

    authors: Calvet CY,André FM,Mir LM

    更新日期:2014-04-29 00:00:00

  • Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

    abstract::Successful cancer immunotherapy necessitates T cell proliferation and infiltration into tumor without exhaustion, a process closely links optimal maturation of dendritic cells (DC), and adjuvant promotes this process as an essential prerequisite. Poly(I:C) has contributed to adjuvant immunotherapy that evokes an antit...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1188244

    authors: Azuma M,Takeda Y,Nakajima H,Sugiyama H,Ebihara T,Oshiumi H,Matsumoto M,Seya T

    更新日期:2016-05-19 00:00:00